Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    Apolipoprotein Ratios Better Than Cholesterol Ratios for Predicting Heart Attack Risk - (DGNews)
    Updated Boxed Warning for Micro-Bubble Contrast Agents - (DGNews)
    European Commission Approves Ranolazine for Treatment of Patients With Chronic Angina - (DGNews)
    TopAbstracts in Angina Pectoris/MI 07/09/2008 - (DGNews)
    Kidney Disease Linked to Lower Medication Use After Heart Attack - (DGNews)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
      Optimizing Antiplatelet Therapy in the ACS Patient: The Intersection of Acute Coronary Syndromes and Oral Antiplatelet Therapy
      Use of Direct Thrombin Inhibitors for Treating Non-St-Segment Elevation Acute Coronary Syndromes in Special Patient Groups: Women, Diabetics, the Elderly, and Chronic Renal Insufficiency
      CRUSADE: Contemporary Evaluation and Management of 200,000 High-Risk NSTE-ACS Patients
      Understanding Chronic Ischemic Heart Disease Today
      Risk Stratification in Patients with Chronic Myocardial Ischemia

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        Diagnostic Uncertainty of Takotusbo Cardiomyopathy Presenting as Acute Myocardial Infarction in a Woman with Cardiovascular Risk Factors Hijacked at Gunpoint: A Case Report
        The Role of Intravascular Ultrasound in the Management of Spontaneous Coronary Artery Dissection
        Unusual Cause of Exercise-Induced Ventricular Fibrillation in a Well-Trained Adult Endurance Athlete: A Case Report
        Myocardial Ischemia in the Absence of Epicardial Coronary Artery Disease in Friedreich's Ataxia
        Double Rupture of Interventricular Septum and Free Wall of the Left Ventricle, as a Mechanical Complication of Acute Myocardial Infarction: A Case Report

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Ranolazine Improves Angina in Patients with Heart Failure: Presented at AHA

        By Jill Stein

        CHICAGO, IL -- November 18, 2002 -- The partial fatty acid oxidation inhibitor ranolazine provides effective antianginal therapy in patients with a history of heart failure who remain symptomatic despite treatment with a beta blocker or calcium channel blocker, researchers announced here November 17 at the American Heart Association's 2002 Scientific Sessions.

        Dr. Harvey White, from Green Lane Hospital, in Auckland, New Zealand, reported results in 823 chronic angina patients who remained symptomatic on diltiazem CD 180 mg qd, atenolol 50 mg qd, or amlodipine 5 mg qd, who were randomized to treatment with ranolazine 750 mg bid, ranolazine 1,000 mg bid, or placebo.

        The trial excluded patients with New York Heart Association class III or IV.

        "Treating the chronic angina patient who also has heart failure can be difficult, as negative haemodynamic effects often accompany traditional antianginal therapies," Dr. White observed. "Newer therapies, like partial fatty acid oxidation inhibitors, have shown potential utility for treating chronic angina with minimal effects on hemodynamics."

        Ranolazine shifts myocardial energy production from fatty acid oxidation to the more oxygen-efficient glucose oxidation, he continued. Because ranolazine exerts its effect without affecting hemodynamics, it may prove especially useful in chronic angina patients with a history of heart failure.

        Patients performed modified Bruce treadmill tests at baseline and at weeks 2, 6, and 12 at trough and peak plasma levels. Overall, 237 patients had a prior history of class I or II heart failure.

        Results showed that ranolazine prolonged exercise duration at trough and peak plasma levels. Similar results were seen in the time to angina and time to 1 mm ST segment depression. Also, ranolazine reduced the frequency of angina episodes.

        While ranolazine's effects did not differ significantly in heart failure and non-heart failure patients (p>0.22), heart failure patients treated with ranolazine 750 mg had smaller improvements in all exercise measures at trough levels.

        Ranolazine was well tolerated in patients with and without heart failure.

        Dr. White said the results suggest that ranolazine is a potentially effective antianginal drug for patients with a history of heart failure who have symptoms despite treatment with a beta blocker or calcium antagonist.

        The study was sponsored by CV Therapeutics in Palo Alto, California, United States.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send